New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania

The Role of Rhetoric and Metaphors in Organisational Change RESUMEN El presente artículo es una recopilación de literatura científica que demuestra la relevancia de comprender nuevas formas de construir el concepto de cambio organizacional a través del lenguaje, en especial a través de claves lingüísticas como la retórica y metáfora. Esta construcción ayuda a generar procesos de cambio organizacional que presenten una menor intensidad y carga emocional negativa para los individuos, así como una mejor comprensión del mismo cambio para los empleados. Palabras clave: cambio, organización, retórica, metáfora. ABSTRACT This article is a compilation of scientific literature about the importance of understanding new approaches to the construction of the organisational change concept through language, especially through linguistic devices such as rhetorical and metaphorical ones. This construction helps the creation of organisational change processes with lower levels of impact and a lower negative emotional burden for individuals as well as a better understanding of such changesKeywords: changes; organisation; rhetoric; metaphor.

Download Full-text

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder

Case Medical Research ◽

10.31525/ct1-nct04211428 ◽

2019 ◽

Author(s):

Keyword(s):

Bipolar Disorder ◽

Pilot Study ◽

Gut Flora

Download Full-text

Faculty Opinions recommendation of Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder: evidence in support of mitochondrial dysfunction hypothesis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726084834.793526786 ◽

2016 ◽

Author(s):

Victor Reus

Keyword(s):

Bipolar Disorder ◽

Cerebrospinal Fluid ◽

Mitochondrial Dysfunction ◽

Isocitrate Dehydrogenase

Download Full-text

The Renin Angiotensin System and Bipolar Disorder: A Systematic Review

Protein and Peptide Letters ◽

10.2174/0929866527666200127115059 ◽

2020 ◽

Vol 27 (6) ◽

pp. 520-528 ◽

Cited By ~ 2

Author(s):

Izabela Guimarães Barbosa ◽

Giulia Campos Ferreira ◽

Diomildo Ferreira Andrade Júnior ◽

Cássio Rocha Januário ◽

André Rolim Belisário ◽

...

Keyword(s):

Systematic Review ◽

Bipolar Disorder ◽

Cardiovascular Diseases ◽

Renin Angiotensin System ◽

Plasma Renin ◽

Angiotensin Receptors ◽

Angiotensin System ◽

Renin Angiotensin ◽

Search Terms

Bipolar Disorder (BD) is a chronic a multifactorial psychiatric illness that affects mood, cognition, and functioning. BD is associated with several psychiatric conditions as well clinical comorbidities, particularly cardiovascular diseases. The neurobiology of BD is complex and multifactorial and several systems have been implicated. Considering that the Renin Angiotensin System (RAS) plays an important role in cardiovascular diseases and that recently evidence has suggested its role in psychiatric disorders, the aim of the present study is to summarize and to discuss recent findings related to the modulation of RAS components in BD. A systematic search of the literature using the electronic databases MEDLINE and LILACS was conducted through March 2019. The search terms were: “Bipolar Disorder”; “Renin Angiotensin System”; “Angiotensin 2”; “Angiotensin receptors”; “Angiotensin 1-7”; “ACE”; “ACE2”; “Mas Receptor”. We included original studies assessing RAS in BD patients. Two hundred twenty-two citations were initially retrieved. Eleven studies were included in our systematic review. In the majority of studies (6 of 8), the ACE insertion/deletion (I/D) polymorphism did not differ between BD patients and controls. BD patients presented higher plasma renin activity in comparison with controls. The studies evaluating the RAS molecules in BD are very scarce and heterogeneous. The literature suggests a potential role of RAS in BD. Further studies are necessary to investigate this relationship.

Download Full-text

Considering a Potential Role of Linalool as a Mood Stabilizer for Bipolar Disorder

Current Pharmaceutical Design ◽

10.2174/1381612826666200724160742 ◽

2020 ◽

Vol 26 (40) ◽

pp. 5128-5133

Author(s):

Kate Levenberg ◽

Wade Edris ◽

Martha Levine ◽

Daniel R. George

Keyword(s):

Bipolar Disorder ◽

Treatment Options ◽

Mood Stabilizer ◽

Well Being ◽

Epidemiologic Studies ◽

Treatment Regimens ◽

Bipolar Spectrum Disorders ◽

Short And Long Term

Epidemiologic studies suggest that the lifetime prevalence of bipolar spectrum disorders ranges from 2.8 to 6.5 percent of the population. To decrease morbidity and mortality associated with disease progression, pharmacologic intervention is indicated for the majority of these patients. While a number of effective treatment regimens exist, many conventional medications have significant side effect profiles that adversely impact patients’ short and long-term well-being. It is thus important to continue advancing and improving therapeutic options available to patients. This paper reviews the limitations of current treatments and examines the chemical compound Linalool, an alcohol found in many plant species, that may serve as an effective mood stabilizer. While relatively little is known about Linalool and bipolar disorder, the compound has been shown to have antiepileptic, anti-inflammatory, anxiolytic, anti-depressive, and neurotrophic effects, with mechanisms that are comparable to current bipolar disorder treatment options.

Download Full-text

Cognitive behaviour therapy meets psychopharmacotherapy

The Cognitive Behaviour Therapist ◽

10.1017/s1754470x10000127 ◽

2010 ◽

Vol 3 (4) ◽

pp. 117-131

Author(s):

David Veale ◽

Anna Stout

Keyword(s):

Bipolar Disorder ◽

Side Effects ◽

Emotional Disorders ◽

Cognitive Behaviour Therapy ◽

Behaviour Therapy ◽

Cognitive Behaviour ◽

Underlying Disorder

AbstractThis article provides an overview of the role of psychopharmacotherapy in common emotional disorders for cognitive behaviour therapists. We consider some of the philosophical difference between CBT and medication, when medication might interfere with CBT, when it may enhance outcome and when it might be safely discontinued. We highlight how to differentiate side-effects and symptoms of discontinuation of antidepressants from that of the underlying disorder. The scope of this article is confined to common emotional disorders and does not discuss the interaction of CBT with medication in, e.g. schizophrenia, bipolar disorder or dementia.

Download Full-text